Subgen AI AB (FRA:52Q0)
Germany
· Delayed Price · Currency is EUR 0.3820
-0.0710 (-15.67%)
At close: Dec 4, 2025
Subgen AI AB Company Description
Subgen AI AB develops and commercializes diagnostic tests for monitoring and optimizing the dosage of biological drugs.
The company develops a testing platform for oral health, therapeutic drug monitoring, and infectious diseases.
It develops Veritope technology used to optimize the dosage of biological drugs to patients; and the MagniaReader platform.
The company was formerly known as Magnasense AB and changed its name to Subgen AI AB in November 2025.
Subgen AI AB was incorporated in 2019 and is based in Lund, Sweden.
Subgen AI AB
| Country | Sweden |
| Founded | 2019 |
| Industry | In Vitro and In Vivo Diagnostic Substances |
| Employees | 15 |
| CEO | Marco Witteveen |
Contact Details
Address: ScheelevAegen 27 Lund, 223 63 Sweden | |
| Phone | 46 4 62 86 54 00 |
| Website | magnasense.com |
Stock Details
| Ticker Symbol | 52Q0 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Lorenzo Serratosa Gallardo | Chief Executive Officer |
| Vicki Johnson | Chief Financial Officer |